MedTrace Logo

Stereotactic Radiosurgery Combination With Anlotinib for Limited Brain Metastases With Perilesional Edema in NSCLC

NCT04147728 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2020-03-04

No results posted yet for this study

Summary

The purpose of this study is to determine whether stereotactic radiosurgery combination with Anlotinib is safe, effective in the treatment of limited brain metastases with Perilesional edema in non-small cell lung cancer.

Conditions

  • Stereotactic Body Radiation Therapy

Interventions

DRUG

Anlotinib

Anlotinib is a novel multi-target tyrosine Kinase inhibitor that inhibits VEGFR2/3, FGFR1-4, PDGFD α/β, c-Kit and Ret.

RADIATION

Stereotactic Radiosurgery

Stereotactic Radiosurgery as the initial treatment of non small cell lung cancer patients with limited brain metastases

Sponsors & Collaborators

  • Huashan Hospital

    collaborator OTHER

  • Tianjin Medical University

    collaborator OTHER

  • Peking University Third Hospital

    lead OTHER

Principal Investigators

  • Hongqing Zhuang, doctor · Peking University Third Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-24
Primary Completion
2021-12-15
Completion
2022-12-15

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04147728 on ClinicalTrials.gov